Concepedia

KellyAnn D. Pryor

KD

13

Publications

814

Citations

13

H-Index

1997

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

KellyAnn D. Pryor is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and biochemistry.

Top concepts

MedicineBiochemistryPharmacologyNatural SciencesDrug DiscoveryMedicinal ChemistryMolecular PharmacologyProteomicsPharmacotherapyDrug Development

Publications per year

1997–2010

13

Publications

13

High-Level Expression of Soluble Protein inEscherichia coliUsing a His6-Tag and Maltose-Binding-Protein Double-Affinity Fusion System

KellyAnn D. Pryor, Barbara Leiting · Protein Expression and Purification · 1997 · 244 citations

Protein Chemistry, Soluble Protein, Protein Expression +10

Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII

Barbara Leiting, KellyAnn D. Pryor, Joseph K. Wu et al. · Biochemical Journal · 2003 · 181 citations · Full text

Proteomic Technology, Molecular Pharmacology, Catalytic Constants +15

Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines

Dooseop Kim, Jennifer E. Kowalchick, Linda Brockunier et al. · Journal of Medicinal Chemistry · 2008 · 60 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +14

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Dooseop Kim, Jennifer E. Kowalchick, Scott D. Edmondson et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 57 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +9

Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity

Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto et al. · Journal of Medicinal Chemistry · 2010 · 51 citations · Full text

Rows per page

1–5 of 13